ARPA Bio
in tune with innovative solutions for early therapeutic intervention...
Analysis of CSF and blood based biomarkers using ARPA Bio's proprietary platform:
ARPA Bio's analytical platform enables the detection of low abundant CSF and plasma biomarkers at the femto to picogram / ml level. We apply our novel antibody tools in combination with the latest, state-of-the-art mass spectrometry technology, to monitor disease specific biomarkers in human biofluid. Our analytical approach allows absolute quantitation of multiple disease associated targets of interest during a single analytical run. This in turn enables monitoring of early disease onset or progression, as well as a patient's response to a therapeutic treatment.
More specific information about our technology will be announced soon....
